Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB11 (Proposed Nivolumab Biosimilar) vs Opdivo in Advanced Melanoma
NCT07221734Phase 3Recruiting
- Sponsor
- mAbxience
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of LY01015 in melanoma, sponsored by mAbxience. Started Dec 2025; status: recruiting.
02
Drugs
LY01015
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07221734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221734.